China Universal Asset Management Co. Ltd. Has $1.64 Million Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

China Universal Asset Management Co. Ltd. lifted its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 63.9% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 142,234 shares of the company's stock after purchasing an additional 55,445 shares during the quarter. China Universal Asset Management Co. Ltd.'s holdings in Roivant Sciences were worth $1,641,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of ROIV. nVerses Capital LLC purchased a new stake in Roivant Sciences in the 2nd quarter worth approximately $34,000. Point72 Hong Kong Ltd acquired a new stake in shares of Roivant Sciences in the second quarter valued at about $36,000. Quarry LP bought a new position in Roivant Sciences in the 2nd quarter worth approximately $53,000. Acadian Asset Management LLC acquired a new position in Roivant Sciences during the 1st quarter valued at $72,000. Finally, Fifth Third Wealth Advisors LLC bought a new stake in shares of Roivant Sciences in the second quarter valued at about $101,000. Institutional investors and hedge funds own 64.76% of the company's stock.

Insider Buying and Selling

In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the company's stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $11.65, for a total transaction of $1,165,000.00. Following the transaction, the chief operating officer now directly owns 617,470 shares in the company, valued at approximately $7,193,525.50. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, COO Eric Venker sold 100,000 shares of the business's stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $11.65, for a total transaction of $1,165,000.00. Following the completion of the transaction, the chief operating officer now directly owns 617,470 shares in the company, valued at approximately $7,193,525.50. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Rakhi Kumar sold 250,000 shares of Roivant Sciences stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $11.89, for a total value of $2,972,500.00. Following the transaction, the chief accounting officer now owns 209,322 shares in the company, valued at approximately $2,488,838.58. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,577,309 shares of company stock worth $42,151,184 over the last three months. 4.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have issued reports on ROIV shares. Piper Sandler boosted their price target on shares of Roivant Sciences from $20.00 to $22.00 and gave the company an "overweight" rating in a report on Wednesday, July 10th. Bank of America raised their price target on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a "neutral" rating in a research note on Wednesday, September 11th. HC Wainwright reiterated a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a research note on Thursday, September 19th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Roivant Sciences in a research note on Thursday, September 19th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $17.39.

Roivant Sciences Price Performance

Shares of NASDAQ:ROIV traded down $0.26 during midday trading on Tuesday, reaching $11.58. The company's stock had a trading volume of 4,995,278 shares, compared to its average volume of 5,924,614. The business's fifty day simple moving average is $11.82 and its 200-day simple moving average is $11.23. The company has a debt-to-equity ratio of 0.05, a current ratio of 27.91 and a quick ratio of 27.91. Roivant Sciences Ltd. has a fifty-two week low of $8.29 and a fifty-two week high of $13.06. The company has a market capitalization of $8.55 billion, a P/E ratio of 2.30 and a beta of 1.24.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.33. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The firm had revenue of $55.10 million during the quarter, compared to analysts' expectations of $30.72 million. During the same quarter last year, the company posted ($0.38) EPS. The company's quarterly revenue was up 155.1% compared to the same quarter last year. As a group, equities research analysts expect that Roivant Sciences Ltd. will post -1.14 EPS for the current fiscal year.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.